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IMAGING-GUIDED THROMBOLYSIS FOR ACUTE ISCHEMIC LACUNAR 
STROKE PAST 4.5 HOURS 
LILY GANZ 
ABSTRACT 
Background: Under the current treatment guidelines for acute ischemic stroke, 
intravenous alteplase may be used within 3-4.5 hours of symptom recognition or in cases 
of unknown onset if there is a small lesion on diffusion weighted imaging without 
increased signal on FLAIR sequence MRI. We seek to determine whether patients with 
lacunar strokes greater than 4.5 hours post onset with a DWI-FLAIR mismatch on 
imaging will benefit from thrombolysis with intravenous alteplase.  
Methods: We will conduct a multicenter, randomized, double-blinded, placebo-
controlled trial of patients presenting with acute ischemic stroke within 4.5 to 6 hours of 
symptom onset with DWI-FLAIR mismatch and without a large vessel occlusion. A 
target of 682 patients will be randomized to receive IV alteplase or placebo. The primary 
outcome is a favorable functional status as defined by a score of 0 or 1 on the modified 
Rankin scale (mRS) at 90 days. The secondary outcome is ordinal score on the modified 
Rankin scale at 90 days. The primary safety end points will be symptomatic intracranial 
hemorrhage (sICH) and death 
Conclusions: If intravenous (IV) alteplase is found to be an effective and safe treatment 
for lacunar stroke with DWI-FLAIR mismatch >4.5 hours from onset, these patients 
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Stroke is a major cause of disability and mortality worldwide. In the United States, there 
are 7.8 million people who have had a stroke during their lifetime. Close to 800,000 
strokes occur each year, which are responsible for 140,000 deaths.1,2 Strokes can also 
result in devastating long term disability for survivors. Long term effects include partial 
paralysis, weakness, speech difficulties, and issues with thinking, memory, or learning.  
 Stroke can occur due to blockage of a blood vessel supplying the brain, which 
leads to oxygen deprivation of the brain tissue, resulting in an ischemic stroke, or due to 
bleeding into or around the brain, referred to as a hemorrhagic stroke. Ischemic strokes 
are more common and are the focus of this thesis.  
 Risk factors for stroke include hypertension, hypercholesterolemia, smoking, 
obesity, and diabetes. At least one of these factors is present in one third of adults in the 
United States.1 Many of these risk factors are modifiable and strokes are largely 
preventable with lifestyle modification.  
 Currently, there are two main treatments available for acute ischemic stroke -- 
pharmacologic thrombolysis with intravenous (IV) tissue plasminogen activator (tPA) 
and mechanical thrombectomy with stent retrieval devices. Mechanical thrombectomy 
can only be performed in cases where there is a large vessel occlusion (LVO), 
specifically blockage of the internal carotid artery (ICA) or proximal portions of the 
anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery 
(PCA), or basilar artery. Under current guidelines, IV thrombolysis with alteplase can be 
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performed up to 3-4.5 hours from last known well and mechanical thrombectomy can be 
performed up to 24 hours from last known well, if advanced imaging criteria are met.3  
 
Statement of the Problem 
 While many advancements have been made in the field of acute ischemic stroke 
treatment, there are still many patients who fall outside of the criteria for either 
thrombolysis or thrombectomy. In addition to those who present to a medical facility 
greater than 4.5 hours from onset, there is also a large percentage of patients who present 
immediately after symptom recognition but have an unknown time of stroke onset, 
particularly in the case of stroke symptoms identified first thing in the morning (known as 
“wake-up” strokes). 
These patients have not classically met the criteria for treatment with 
thrombolysis and have only been eligible for thrombectomy if they have a large vessel 
occlusion. This past year, the stroke guidelines have been modified to allow for treatment 
with IV alteplase in a select group of patients who present with wake-up stroke when 
imaging criteria are met. Patients with lacunar strokes also often do not meet treatment 
criteria. Lacunar stroke is defined as a non-LVO stroke that occurs in deep, subcortical 
regions of the brain and is classically attributed to disease of the smallest vessels in the 
cerebrovascular network. These lacunar strokes account for 15-25% of all strokes in the 
US and Europe and have limited treatment options if they present in the later time 
window, since this stroke subtype is not eligible for mechanical thrombectomy.4 
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 Recent research has demonstrated that there is value in using advanced imaging to 
evaluate an individual patient’s degree of salvageable brain tissue in order to make 
treatment decisions based on a “biological clock” rather than standardized time cutoffs 
derived from population studies. The time to complete infarction varies in individuals 
based on several factors including hemodynamics, collateral circulation, and metabolic 
demand. Advanced imaging including CT and MR perfusion and MRI comparing DWI 
and FLAIR sequences, can help differentiate areas of salvageable hypo-perfused and 
irreversibly infarcted tissue. These techniques have already changed the standard of care 
for endovascular thrombectomy as they are used to determine a patient’s candidacy for 
thrombectomy beyond 6 hours from symptom onset. However, using advanced imaging 
to make decisions about giving alteplase in later time windows and for wake-up strokes is 
an area of active investigation. In particular, no major studies have been performed using 




Patients presenting with stroke symptoms between 4.5-6 hours of symptom onset, 
without a large vessel occlusion seen on imaging, and with DWI-FLAIR mismatch on 
MRI, will have a favorable functional outcome with IV tPA (alteplase) treatment 




Objectives and Specific aims 
 The objective of this thesis is to investigate the utility of IV thrombolysis for 
treatment of acute, ischemic, lacunar stroke with favorable perfusion imaging profiles in 
an extended time window. The primary outcomes will be disability at 90 days. Disability 
will be measured with the modified Rankin Scale (mRS) and safety measured by the rate 
of symptomatic intracerebral hemorrhage (sICH). Specifically, this thesis aims to: 
• Compare the rate of favorable outcome, defined as mRS 0-1 at 90 days, in the 
alteplase and placebo group 
• Compare ordinal mRS scores in the alteplase and placebo groups  
• Compare differences in rate of sICH at 36 hours post treatment and rate of death 




REVIEW OF THE LITERATURE 
Overview 
Epidemiology 
 In the United States, nearly 800,000 people experience a new or repeat stroke 
every year, about one every 40 seconds.1 Ischemic strokes are much more common than 
hemorrhagic strokes and account for about 87 percent of strokes. The mortality rate is 
high and in the United States, stroke is the 5th most common cause of death. With 
advances in stroke treatment including thrombolytic therapy, the age-adjusted death rate 
fell 28.7% from 2004 to 2014. In addition to mortality, stroke is a major cause of long-
term disability, causing loss of mobility in more than 50 percent of older adults. There is 
also significant loss of functional independence with activities of daily living in stroke 
survivors. In addition, stroke care represents a major health expenditure and costs the 
United States roughly $34 billion a year. Stroke is more common in older adults but it 
affects people of all ages. Additionally, there are profound racial and geographic 
disparities in the effects of stroke. Black patients have almost twice the risk of stroke and 
experience the highest mortality rate from stroke. Additionally, mortality rates are 
significantly higher along a “stroke belt” in the South. 1,5   
 Timing is crucial in the treatment of stroke because every minute of ischemia 
leads to more tissue death and thus the common phrase, “time is brain.” Currently, both 
of the major therapies for stroke are time-dependent so it is important to note that 
approximately 25-30% patients with acute stroke present with an unknown time of 
symptom onset6 and another subset of patients present with known time of onset beyond 
 
6 
the maximum times allowed for either intervention. Between 2005 and 2011 only 3.8% 
of patients with acute ischemic stroke received treatment with IV tPA7 largely due to the 
strict time restraints.  
 
Risk factors/Prevention 
 The major risk factors for stroke can be separated into modifiable and 
nonmodifiable factors. Examples of nonmodifiable risks factors are age, family history, 
race, and gender with a greater incidence of stroke occurring in older patients, patients 
with a positive family history, African-Americans, and women. However, there are many 
modifiable risk factors for stroke and the American Stroke Association reports 80% of 
strokes could be prevented.8 Modifiable risk factors include high blood pressure, 
diabetes, smoking, lack of physical activity, poor diet, obesity, high cholesterol, and atrial 
fibrillation. 
 Hypertension remains the most significant cause of stroke and is highly 
modifiable with diet, exercise, and anti-hypertensive medications. Smoking is another 
major contributor to stroke risk due to the direct damage cigarette smoke causes to blood 
vessels. Accordingly, smoking cessation is a key behavior targeted in stroke prevention. 
There is also a strong association between diabetes and stroke with 16% of patients 65 
and older with diabetes dying from strokes.8 Diabetes treatment is important in mitigating 
risk but the presence of diabetes, even if well controlled, is an independent risk factor for 
stroke. Diets high in fat, sodium, and cholesterol should be avoided and lifestyle 
interventions should be implemented to increase physical activity and promote weight 
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loss. Hypercholesterolemia, specifically high low-density lipoprotein (LDL), contributes 
to atherosclerosis and clot formation, which can lead to ischemic stroke. Fortunately, 
statin therapy is a very effective treatment and a mainstay in stroke prevention. Patients 
with atrial fibrillation are five times more likely to suffer a stroke due to clot formation in 
the heart that can embolize to the cerebrovascular system. Patients with atrial fibrillation 
are routinely put on anticoagulation for stroke prevention, though even with reliable use 
of these medications stroke risk is only reduced by 60-70%.  
 In addition to prevention of first-time stroke, secondary prevention is emphasized 
for patients after their first stroke. In these cases, it is important to identify the etiology of 
the stroke and address modifiable risk factors that will impact secondary prevention. 
Common testing in the setting of recent stroke includes cardiac monitoring to identify 
arrhythmias, echocardiography to identify thrombi in the heart or a patent foramen ovale, 
imaging of the extracranial and intracranial arterial system, lipid testing to measure 
cholesterol levels, and hemoglobin A1c for diabetes. Based on the etiology and risk 
factors present, secondary prevention measures can be taken.  
 
Pathophysiology  
 An acute ischemic stroke occurs due to reduction or cessation of blood flow to the 
territory of brain tissue supplied by an affected vessel.9 If blood flow is not returned, then 
infarction of the tissue occurs, leading to irreversible damage. If blood flow is returned to 
the tissue before infarction occurs, symptoms may resolve and it is considered a transient 
ischemic attack. Occlusion can be due to a thrombus resulting from a ruptured plaque, an 
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embolus that traveled from the heart or great vessels, or atherosclerotic narrowing of a 
vessel. The degree of blood flow reduction is dependent on an individual’s collateral 
vessel anatomy, blood pressure, and site of occlusion. If the blood flow is completely 
blocked, tissue death will result in 4-10 minutes.10 A reduction in flow to 16-18 mL/100g 
tissue will result in infarction within one hour, while a flow of 18-20 mL/100 g tissue will 
result in tissue ischemia without infarction. Reversibly ischemic tissue surrounding an 
infarcted tissue core is referred to as the “ischemic penumbra”, a concept which is 
important in determining eligibility for late treatment with thrombolysis or endovascular 
thrombectomy.  
 The mechanism involved in tissue infarction depends on the degree of ischemia. 
In severe ischemia, the necrotic pathway predominates. Cells are deprived of glucose and 
oxygen, which leads to mitochondrial failure and inability to produce ATP. Ion pumps 
fail without ATP and neurons depolarize, causing calcium influx into cells, as well as 
glutamate release from synaptic terminals, a neurotoxic neurotransmitter. Lipid 
membrane breakdown and mitochondrial dysfunction produce catalytic free radicals 
which further disrupt cell function. In the less ischemic penumbra, the apoptotic pathway 
predominates, which leads to more controlled, programmed cell death. Fever and 
hyperglycemia worsen the degree of injury during ischemia and are treated aggressively 
in ischemic strokes.  
 In order to understand the mechanism of action of alteplase, a recombinant form 
of tissue plasminogen activator, it is necessary to discuss the physiological mechanism of 
in vivo tPA. When the coagulation cascade is activated in the body, a counterregulatory 
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fibrinolytic cascade is initiated to limit the size of the clot and later dissolve the clot. The 
primary fibrinolytic agent is the protease plasmin. Inactive circulating plasminogen is 
cleaved by the factor XII pathway or tissue activators to form plasmin. Plasmin breaks 
down the fibrin in the clot and inhibits further fibrin polymerization. Synthesized by the 
endothelium, tPA is the most significant of the plasminogen activators. Because it is most 
active when it is bound to fibrin, its activity is limited to areas of thrombosis.11 
 
Imaging 
Imaging is critical for the evaluation of stroke. Neuroimaging studies can distinguish 
between an ischemic and a hemorrhagic stroke, identify an occluded vessel, and identify 
salvageable tissue to determine eligibility for intervention. The current standard of care 
for patients presenting with stroke-like symptoms who may be eligible for intervention is 
to first obtain a non-contrast CT scan immediately to rule out a hemorrhage. CT is fast 
and widely available but non-contrast CT is limited in the detection of ischemia in the 
first 24-48 hours. There are several alternative imaging options to evaluate ischemia in 
this early time window. MRI is a very effective modality for identifying areas of 
infarction and hemorrhage within the brain. There are several different MRI imaging 
sequences useful in the evaluation of stroke including diffusion weighted imaging (DWI), 
apparent diffusion coefficient (ADC), Fluid-attenuated inversion recovery (FLAIR), and 
Susceptibility Weighted Imaging (SWI). DWI is the most sensitive in detecting early 
ischemia and infarction and is important in the acute setting. FLAIR is also sensitive for 
infarction9, although hyperintensity due to infarction appears later on FLAIR than on 
 
10 
DWI. Therefore, a comparison of DWI and FLAIR sequences can distinguish ischemic 
tissue from infarcted tissue in order to identify a potentially salvageable region (Figure 
1). SWI is important for identifying blood products which can indicate petechial 
hemorrhages. A CT or MR angiogram with contrast can be performed to visualize the 
cervical and intracranial arteries to determine the location of the occluded vessel. CT or 
MR perfusion studies can be used to estimate the region of infarcted tissue and area at 
risk of infarction, called the “ischemic penumbra.”9 RAPID is a novel neuroimaging 
software used in some recent clinical trials. RAPID interprets and displays high quality 
images of CT/CTA, CT MR Perfusion, and DWI-FLAIR in easy-to-interpret views that 
highlight abnormal hemodynamics and areas of ischemia that can be displayed on mobile 
phone, email, or hospital imaging viewers.  
 
 
Figure 1. DWI-FLAIR Mismatch on MRI  
(Adapted from Rimmele and Thomalla et. al 2014)12 
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Current Treatment Guidelines 
The current treatment modalities for ischemic stroke are IV tPA and endovascular 
thrombectomy. All suspected stroke patients should have a non-contrast head CT to rule 
out hemorrhagic stroke. If a hemorrhage is not identified, eligibility for tPA is then 
evaluated. If a patient is eligible to receive tPA, it should be given regardless of whether 
they are being considered for endovascular thrombectomy as well. A CT or MR 
angiogram should also be performed to assess for a large vessel occlusion in patients 
presenting with characteristic symptoms. For patients who are potential candidates for 
tPA for wake-up stroke or thrombectomy past 6 hours, advanced imaging such as CT 
perfusion (CT-P), MR perfusion (MR-P), or DWI-FLAIR MRI may also be necessary.3 
Additionally, an MRI is usually performed eventually in any patient with a stroke to 
further characterize the location and extent of the stroke and identify any hemorrhage not 
visible on CT.   
Alteplase (rt-PA) is the only thrombolytic drug approved for the treatment of 
ischemic stroke, but there are strict criteria for its use (Table 1). The target effect is 
thrombolysis and, ultimately, recanalization of the thrombosed vessel. It is believed to 
have a time-dependent effect and use within 3 hours of stroke onset is the standard of 
care, with use up to 4.5 hours recommended in certain circumstances. Additionally, in 
2019 the guidelines were updated to state that IV alteplase may be given to patients who 
wake up with stroke symptoms or have an unknown time of onset greater than 4.5 hours 
from their last known well, if they meet imaging criteria and alteplase is given within 4.5 
hours of symptom recognition. These imaging inclusion criteria are the presence of a 
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diffusion weight MRI lesion <1/3 of the MCA territory and no signal on FLAIR.13 A 
door-to-medication administration time of less than 60 minutes is recommended.  
Table 1. Eligibility for Thrombolysis 
Inclusion Criteria 
-Diagnosis of ischemic stroke causing significant neurologic deficit 
-Symptom onset < 4.5 hours 
-Age > 18 
Exclusion Criteria 
-Ischemic stroke, severe head trauma, intracranial or spinal surgery in past 3 months 
-Prior intracranial hemorrhage 
-Intra-axial intracranial neoplasm 
-GI malignancy or hemorrhage within 21 days 
 
Clinical 
-Evidence of intracranial hemorrhage 
-Persistent hypertension (systolic > 185 mmHg or diastolic > 110 mmHg) 
-Active internal bleeding or bleeding diathesis 
-Suspected Infective endocarditis or aortic arch dissection  
-Platelet count <100,000 
-Current anticoagulant use with INR > 1.7, PT > 15 s, or aPTT > 40 s 
-Low molecular weight heparin at therapeutic dose within 24 hr 
-Direct thrombin inhibitor or direct factor Xa inhibitor w/ lab evidence of -anticoagulant 
effect  
-Extensive areas of hypodensity on imaging 
 
Relative Contraindications 
-Serum glucose <50  
-Serious trauma or major surgery within 14 days 
-History of GI or GU bleeding 
-Seizure at stroke onset 
-Pregnancy 
-Arterial puncture at a non-compressible site in last 7 days 
-Intracranial aneurism > 10 mm 
-Intracranial vascular malformation 
 
Additional warning for 3 to 4.5 hours from symptom onset 
-Age > 80  
-Oral anticoagulant use (independent of INR) 
-NIHSS score > 25 
-Prior ischemic stroke and history of diabetes mellitus 
(Adapted from UpToDate 2019)14 
 
Endovascular thrombectomy is a treatment option for patients with occlusion of the 
internal carotid, middle cerebral artery, or basilar artery. Occasionally, it is also 
performed on occlusions of the anterior or posterior cerebral arteries. Patients are eligible 
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for thrombectomy if they are within six hours of stroke onset, are age 18 or older, have a 
National Institute of Health Stroke Scale (NIHSS) score above six, have a non-contrast 
head CT that rules out hemorrhage, and have an ASPECT Score > 6. The Alberta Stroke 
Program Early Computed Tomography Score (ASPECTS) is a numerical score that 
demonstrates the extent of tissue involvement seen on head CT and helps predict patient 
outcome. One point is subtracted from 10 for each specified brain region affected, so 
lower scores indicate worse outcomes. In patients presenting past six hours from onset, 
advanced imaging, such as CT-P or MR-P, or MRI with DWI and FLAIR sequences 
should be considered. Patients with significant ischemic-infarction mismatch on 
advanced imaging may be eligible for endovascular thrombectomy up to 24 hours.3  
 
Existing Research 
Major progress has been made in ischemic stroke assessment and treatment over the past 
30 years. Stroke neurology has been an evolving field in which the standard of practice 
has changed several times in response to important studies. 
 The flagship, practice-changing study that demonstrated the efficacy of IV 
thrombolysis for acute ischemic stroke emerged in 1995. The National Institute of 
Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group conducted the 
first randomized, controlled trial to evaluate the clinical efficacy and safety of IV tPA 
(alteplase) for acute ischemic stroke within 3 hours of symptom onset. The trial was 
double-blinded and placebo-controlled. The trial included 291 patients and had two 
phases. Part one evaluated whether alteplase produced improvement of neurological 
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deficits after 24 hours, while the second phase examined sustained clinical and functional 
improvement at 90 days post-treatment according to four global outcome measures, 
including the NIHSS score, Barthel Index, mRS, and Glasgow outcome scale (Appendix 
A).15 The results of both phases of the trial were stratified based on time to treatment. 
 The trial revealed a profound difference in all global outcome measures. Patients 
treated with alteplase were 32% (absolute 12%) more likely to have mild or no disability 
according to the Barthel Index than the placebo group patients at 90 days. Mortality at 90 
days was also lower in the alteplase group compared to the placebo group at 17% and 
21%, respectively (p=0.30). Surprisingly, a statistically significant difference was not 
seen for the primary outcome, defined as improvement of NIHSS score by 4 or more 
points at 24 hours. Though not statistically significant, post-hoc analysis demonstrated 
clinically significant lower median NIHSS scores for patients in the alteplase group 
(median NIHSS score 8 and 12 respectively; p=0.21). A higher incidence of symptomatic 
intracerebral hemorrhage (sICH) within 36 hours was observed in the treatment group 
with a risk of 6.4% compared to 0.6% in the placebo group. It was noted that patients 
who experienced sICH started with more severe neurological symptoms. Thus, giving 
alteplase to acute ischemic stroke patients provided significant functional benefits as well 
as moderate risk. For these reasons, it is only given to patients in whom the benefits 
outweigh the risks, based on published guidelines. Ultimately, clinical judgement is 
imperative in the decision to treat with alteplase. 
 The results of this trial revolutionized ischemic stroke treatment and the eligibility 
criteria for tPA were largely derived from the protocols used in the NINDS trial. The trial 
 
15 
was impactful because it included a relatively large sample size and heterogeneous types 
of ischemic stroke. One limitation of the study was the strict exclusion criteria, which 
ultimately limited the generalizability of the trial and the subset of ischemic stroke 
patients who would be eligible for treatment with IV tPA going forward. Additionally, 
the definition used to determine sICH was broad and subjective and may have included a 
larger percentage of patients than the stricter criteria used in subsequent trials.  
 Despite the success of this trial and resulting international recommendations for 
tPA treatment for acute ischemic stroke less than three hours from onset, less than 2% of 
stroke patients worldwide received tPA. This was most commonly due to delayed 
presentation to a stroke center.16 With such a narrow time window, most patients were 
not eligible for thrombolysis. A pooled analysis of the NINDS study and six other 
randomized trials found a strong association between earlier time to treatment and 
favorable outcome that persisted up to 4.5 hours. This analysis encouraged further 
investigation into treatment in a later time window. In 2008, the ECASS III trial found 
that alteplase treatment between 3 and 4.5 hours from symptom onset was correlated with 
more favorable outcomes than treatment with placebo but with more symptomatic 
intracranial hemorrhages. The study included 821 patients, aged 18-80, clinically 
diagnosed with stroke. The primary end point of the trial was disability at 90 days with a 
favorable outcome defined as an mRS score of 0-1. A favorable outcome was achieved in 
52% of patients in the alteplase group versus 45.2% in the placebo arm (OR 1.34; 95% CI 
1.02-1.76, P=0.04). Remarkably, the number needed to treat to produce one favorable 
outcome was only 14. The secondary end point evaluated the four global outcome scales 
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used in the NINDS trial and the global analysis favored the alteplase group as well with a 
global outcome OR of 1.28 (95% CI 1.00-1.65, P<0.05). The alteplase group had a higher 
rate of sICH than the placebo group, 2.4% and 0.2% respectively. Post-hoc analysis, 
which adjusted for NIHSS score and time from onset to treatment, maintained 
significance for the primary outcome. The trial was impactful because it was strongly 
powered at 90% power and end points were evaluated by dichotomized outcomes, as well 
as global outcome. The trial changed the standard of care to allow for treatment up to 4.5 
hours after symptom onset and established new exclusion criteria for treatment between 
3-4.5 hours post-onset.  
 One limitation of the study was the relatively low median NIHSS score of patients 
in the trial. The alteplase arm had a median NIHSS score of 9 and the placebo arm had a 
median of 10, which limits the generalizability to patients with more severe strokes. 
Another limitation is that there was no method used to stratify patients who would be 
more likely to benefit from late therapy like the imaging methods used in later studies. 
This may have contributed to a higher incidence of adverse outcomes. Lastly, a limitation 
cited by the study is the concern that treatment could be unnecessarily delayed if 
clinicians perceive that there is no rush to meet the 3-hour window. However, limiting 
“door to needle” time remains critical.  
 The next advancements in the field came from imaging patients with unknown 
time of stroke onset to identify patients who would benefit from thrombolytic therapy. 
The idea was that advanced imaging could select good treatment candidates based on 
their individual physiologic response to their stroke, a so-called “biological clock”, rather 
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than standardized time windows based on population-wide data. The MR WITNESS trial, 
published in 2017, broke new ground by evaluating alteplase treatment in ischemic stroke 
patients 4.5-24 hours from last known well with a DWI-FLAIR mismatch on imaging. 
The trial was a phase 2, non-randomized, safety study that included 80 patients, aged 18-
85 with disabling neurologic deficits and confirmed ischemic stroke on MRI.   
 The trial did demonstrate safety in terms of sICH with only one patient (1.3%) 
later diagnosed with sICH. The secondary outcome of functional status at 90 days 
showed a favorable outcome (mRS 0 or 1) in 39% of participants and up to 48% for 
patients with non-LVO strokes. Prior retrospective studies had suggested the comparison 
of DWI and FLAIR sequences could be used as a “tissue clock” for brain ischemia with 
DWI positive, FLAIR negative imaging suggestive of a stroke that started within 
approximately 4.5 hours and would likely benefit from treatment. However, this was the 
first clinical trial to use quantitative evaluation of DWI-FLAIR mismatch rather than 
subjective interpretation of imaging. Additionally, this study expanded the study 
population from previous trials by including patients with unwitnessed and wake-up 
strokes with unknown times of onset.  
The greatest limitation of the trial was its size. This was a small trial designed to 
test for safety, not efficacy. The other major weakness was that the trial was non-
randomized with no comparison group. Additionally, median NIHSS score was 7, lower 
than both the NINDS and ECASS III trials, and it is known that lower NIHSS scores 
portend a better outcome. Patients with pre-existing disability were not excluded from the 
study either, making interpretation of their outcomes less clear. Additionally, the 
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generalizability is limited because using MRI imaging to determine eligibility for tPA is 
restricted by the availability of emergent MRI and the time required to perform MRI 
studies. However, the trial was a strong first step in the direction of using image guidance 
in selection for treatment of patients with unwitnessed strokes.6 
 In addition to tPA research, advances in mechanical interventions for large vessel 
occlusion strokes have made a large impact in the field of stroke treatment. Until 
recently, thrombectomy was limited to within 6 hours of symptom onset. In 2017, two 
landmark trials were published that loosened the time restrictions for mechanical 
thrombectomy in select circumstances. The DAWN trial investigated the use of 
endovascular thrombectomy in patients 6-24 hours from last known well with acute LVO 
stroke and mismatch between imaging and clinical severity. This multicenter, 
randomized-controlled trial investigated 206 patients with clinical features suggestive of 
severe stroke, but imaging with small infarct size suggestive of a large area of 
salvageable brain tissue. Infarct size was evaluated with either DWI or CT-P and 
randomization was stratified based on age, infarct volume, and NIHSS.   
 The trial found that patients in the treatment group had significantly less disability 
at 90 days. The rate of functional independence was 49% for patients who underwent a 
thrombectomy and 13% in the standard care group at 90 days (95% CI, 24 to 44).17 In 
fact, the trial was stopped early due to its profound success. More cases of sICH were 
seen in the thrombectomy group than in the standard of care group, but rate of sICH did 
not differ significantly and nor did 90-day mortality. The number needed to treat was 
only 2-3 patients, making the clinical impact of the results meaningful.17 
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 A strength of the trial was the high median NIHSS score of 17, indicating that this 
treatment could be meaningful for patients with more severe strokes. Another strength 
was the flexibility of imaging (MRI or CT-P) which allowed more centers to participate. 
One major limitation of the study was that RAPID automated imaging interpretation 
software was used, which is costly and not widely available, limiting the feasibility of 
applying the inclusion criteria in practice. Additionally, there were more patients with 
wake-up strokes in the thrombectomy group and a higher rate of co-treatment with 
alteplase in the standard care group. Despite its limitations, this trial had a profound 
impact on the stroke community and changed the standard of practice for LVO stroke 
treatment beyond 6 hours.  
 The DEFUSE 3 trial was another multicenter, randomized thrombectomy trial 
with blinded outcome measures. The trial evaluated patients with last known well of 6-16 
hours with LVO and favorable mismatch on perfusion imaging randomized to 
endovascular thrombectomy with standard medical therapy or medical therapy alone. 
Only 182 patients were randomized of the planned 200 for interim analysis before the 
trial was concluded early given the results of the DAWN trial and loss of equipoise. 
Again, patients in the treatment group had better outcomes, with lower ordinal scores 
overall on the mRS at 90 days (OR 2.77, 95% CI, 1.63-4, p<0.001) and a better chance of 
functional independence, 45% compared to 17% (p<0.001). RAPID software was used to 
interpret the perfusion imaging studies and identify regions of tissue that were ischemic 
but not infarcted. Criteria for inclusion included infarct core <70cc, mismatch ratio > 1.8 
and penumbra > 15cc. The study criteria differed from the DAWN trial which was 
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limited to smaller infarct volumes and depended on age and NIHSS score.18 The majority 
of patients had an unknown time of symptom onset, again highlighting the importance of 
using imaging findings instead of time alone to determine appropriate treatment. The 
major factor limiting generalizability of this study was the requirement of baseline 
perfusing imaging and use of RAPID software to determine eligibility.  
 After the publication of the these two studies, the standard of practice changed to 
incorporate endovascular thrombectomy for patients with large vessel occlusions who 
meet DAWN and DEFUSE 3 eligibility criteria, with treatment administration up to 16 
hours recommended and treatment up to 24 hours considered reasonable.3 While 
impactful, the requirement of advanced imaging and expensive software, as well as the 
strict inclusion criteria, still left a large proportion of patients who did not qualify for the 
therapy. The new guidelines also hindered some of the research that was underway on 
extended time window tPA and tPA for wake-up stroke due to the availability of a non-
investigational option for these patients.  
 Around the same time, a large study investigating treatment of wake-up ischemic 
stroke with IV alteplase was published. It had been postulated that most wake-up strokes 
happen shortly before awakening and, thus, may fall into the accepted time window for 
alteplase administration.12 The 2018 WAKE-UP trial, with 503 patients, was the first 
major randomized-controlled trial that investigated IV alteplase for wake-up strokes 
based on imaging suggestive of recent infarct. Patients with unknown time of onset and 
DWI-FLAIR mismatch who were given IV alteplase had superior functional status at 90 
days than patients given placebo. This was evidenced by a 90-day mRS of 0-1 in 53.3% 
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of patients in the alteplase group compared to 41.8% in the placebo group (p=0.02). 
Notably, the median mRS was 1 point in the alteplase group compared 2 points for 
placebo patients. While there was a higher rate of sICH and death in the treatment group, 
the difference was not statistically significant and most deaths were due to non-stroke 
related causes. The median time from symptom discovery to treatment was 3.1 hours, 
indicating that time from actual onset of stroke may have been over 4.5 hours but positive 
results were still notable. Unfortunately, the lack of availability of emergent MRI in 
many places limits the applicability of this selection technique. Additionally, the trial was 
terminated early because of loss of funding so only 503 of the anticipated 800 patients 
were enrolled, which did not provide enough power for subgroup analysis. The median 
baseline NIHSS was low at 6, which may explain in part the positive results of the study. 
Despite some limitations, the trial broke new ground and suggested that MRI imaging can 
be used to risk stratify patients with unsure time of stroke onset who would safely benefit 
from IV tPA. 
 With the adoption of thrombectomy as the standard of care for LVO strokes, 
research focus shifted to non-LVO ischemic strokes, many of which are clinically 
suspected to be lacunar infarcts. In 2019, Barow et. al published a post-hoc analysis of 
the data from the WAKE-UP trial exploring outcomes of 108 patients with lacunar 
infarcts. The analysis found a non-statistically significant favorable functional outcome 
for patients with lacunar strokes treated with alteplase compared to placebo. 59% of 
treated patients had a mRS of 0-1 at 90 days compared to 46% in the placebo group 
(adjusted OR 1.67; 95% CI 0.77-3.64), as well as a non-significant favorable outcome in 
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the ordinal shift analysis.19 Additionally, there was no significant difference between 
patients with lacunar and large vessel infarcts in treatment outcome, challenging the idea 
that alteplase may not be as beneficial for lacunar strokes. The post-hoc analysis defined 
lacunar infarcts based off of imaging parameters rather than clinical judgement, as is 
often done in studies, making the results more clinically objective. The WAKE-UP trial 
did not have sufficient power to make definitive determinations from subgroup analyses 
but the results suggest that patients with lacunar stroke could potentially have improved 
functional outcome after treatment with IV alteplase.  
 Additionally, after the major thrombectomy trials demonstrated that imaging 
could accurately identify patients who would benefit from treatment with thrombectomy, 
it remained unknown whether these imaging techniques could also select for patients who 
would benefit from treatment with IV tPA in a later time window. The 2019 EXTEND 
trial, a phase 3 multicenter, placebo-controlled trial, randomized 225 patients (113 to the 
alteplase arm and 112 to the placebo arm) who were 4.5 to 9 hours from last known well 
or who woke up with stroke symptoms, with areas of potentially reversible hypo-perfused 
tissue on automated perfusion imaging to treatment with alteplase or placebo.20 Patients 
were eligible for the trial if they were age 18 or older, had good functional status before 
enrollment, had an NIHSS score 4-26, and had a perfusion lesion to ischemic core 
mismatch ratio greater than 1.2. 
  The primary outcome of an mRS 0-1 was attained in 35.4% of patients in the 
treatment arm versus 29.5% in the placebo arm (adjusted risk ratio 1.44; CI 1.01 to 2.06). 
In contrast to the original NINDS trial, patients in the alteplase group had significantly 
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improved neurologic function at 24 hours with major improvement noted in 23.9% of 
patients compared to 9.8% in the placebo group.  
 One strength of the trial was that it had a higher median NIHSS score than 
previous trials including the WAKE-UP and MR WITNESS trials, making the results 
more generalizable. The trial did have some limitations. First, the trial was ended early 
due to loss of clinical equipoise following publication of the WAKE-UP trial despite the 
differences in the study designs and patient populations, which resulted in enrollment of 
only 225 of the intended 400 patients. Due to lower enrollment, the statistical analysis 
was underpowered. Second, average time from presentation to drug administration was 
two hours, exceeding recommended guidelines, which could have led to a less profound 
improvement in outcome or more adverse outcomes. Because the median perfusion 
deficit was greater than 70ml, the results are likely not generalizable to lacunar strokes 
and further investigation is needed. Again, a large proportion of the studied patients 
presented with wake-up strokes, further demonstrating benefit to this patient population. 
A larger study is indicated to evaluate patients in this extended time window.  
 Overall, major progress has been made in ischemic stroke treatment research in 
recent years. The DAWN and DEFUSE-3 trials made breakthroughs in the treatment of 
large vessel occlusion strokes and established guidelines for the using imaging to 
distinguish patients with salvageable brain tissue amenable to mechanical thrombectomy. 
The WAKE-UP and EXTEND trials in turn revolutionized wake-up stroke treatment. 
Due to the results of these trials, patients who awaken with stroke symptoms are eligible 
for treatment with IV alteplase if they meet established imaging criteria, and patients with 
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LVO strokes may be eligible for treatment with thrombectomy up to 16 hours from last 
known well. However, there is still a gap in the research concerning non-LVO stroke, or 
lacunar strokes with known onset over 4.5 hours prior to presentation. These patients are 
not currently eligible for either thrombolysis or mechanical intervention and can suffer 







This trial will be a multi-center, randomized, double-blinded, placebo-controlled trial. 
The trial will investigate the efficacy and safety of IV tPA (alteplase) for patients with 
acute, ischemic, non-LVO strokes and DWI-FLAIR mismatch between 4.5 and 6 hours 
of symptom onset.  
 
Study population and sampling 
The study population will include patients with acute, ischemic strokes demonstrated by 
MRI, without evidence of large vessel occlusion, who otherwise meet criteria to receive 
IV alteplase. To maximize generalizability, the study will be a multi-center trial at 100 
major stroke centers across the United States. Included centers will be primary or 
comprehensive stroke centers with a neurologist on site and availability of emergent 
MRI. Patients presenting to the Emergency Department with symptoms concerning for 
stroke will be screened and consented for the study, if appropriate.  
Inclusion Criteria 
  Subjects will be eligible for the trial if they have symptoms of acute stroke, meet 
imaging criteria, and are able to receive the study drug within 4.5 – 6 hours of symptom 
onset. Other inclusion criteria are age >18, meeting standard tPA criteria (Table 1), and 
ability to perform tasks of daily living prior to onset of stroke symptoms. Additionally, 
only patients with hyperintensity on DWI, without matching increased signal on FLAIR 





Exclusion criteria will include hemorrhage on non-contrast CT, large vessel occlusion by 
CTA or MRA, standard contraindications to tPA, baseline mRS > 1, and severe strokes 
defined at NIHSS >25. An overview of the screening and randomization protocol is 
presented below (Figure 2.).  
 
 
Figure 2. Enrollment and Randomization 
 
Sample size 
 The sample size calculation is modeled off of the effect size found in the WAKE-
UP trial which had a favorable outcome in 53% of treated patients and 42% of patients 
receiving placebo drug.21 The expected absolute between-group difference will be 11% 
for the primary outcome. The calculated sample size is 682 to provide a power of 80% 





















treatment failures, study dropout, and protocol violations, target enrollment will be 758 
patients, 379 per trial group.  
 
Randomization and treatment  
Patients will undergo randomization through a web-based program. Patients will be 
divided between the alteplase and placebo arms in a one-to-one ratio. Patients will 
receive IV alteplase 0.9 mg/kg body weight given as a bolus followed by an infusion or 
matching placebo. All patients and study personnel will be blinded. The study drug will 
be provided as lyophilized powder in glass vials by a distribution center labeled by code 
only. A data safety and monitoring board will monitor the trial regularly to ensure the 
safety of the trial subjects. The safety of the trial will be evaluated after the 
randomization of 100 participants and at the halfway point of the trial. The board will be 
given grouped data about allocation of treatment but will not be unblinded. The board 
will be independent and will not be involved in any other aspects of the trial. At any time, 
the board may suggest alterations to the trial protocol or cessation of the trial due to 
safety concerns.  
 
Study Variables and Outcome Measures 
The primary efficacy end point of the trial will be a favorable functional outcome as 
defined by a modified Rankin scale score of 0-1 at 90 days (Appendix 1). The secondary 
efficacy end point will be ordinal mRS at 90 days. Secondary analysis will stratify results 
based on time to treatment. The primary safety end points will be symptomatic 
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intracranial hemorrhage and death. Other variables of interest will be baseline 




All patients presenting with symptoms concerning for acute stroke will be screened for 
eligibility by the clinicians in the Emergency Department. Eligible patients will be 
recruited and consented for the trial by either the Emergency Department physician or 
neurologist on the stroke response team. In cases where the patient is unable to provide 
consent, next of kin or legal guardian will be consented. Enrollment will occur over three 
years or until 750 patients are enrolled.   
 The WAKE-UP trial recruited 503 patients meeting eligibility criteria across 61 
sites over a period of five years, averaging about 1.6 patients per year per center.21 
Because this study will exclude large vessel occlusion stroke, there is a smaller pool for 
recruitment. However, with 100 sites and more robust recruitment, it is anticipated that 
758 participants will be recruited in 3 years at a rate of 2.5 patients per site per year. 




Data will be collected by clinical assessment at time of randomization and subsequent 
follow up assessment and from the Electronic Medical Record (EMR). All data will be 
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stored in electronic spreadsheets with coded patient IDs to maintain confidentiality and 
treatment codes to maintain blinding.  
 
Clinical assessment 
Clinical assessment will occur at time of stroke, 36 hours post onset, and 90 days post 
onset. A clinician trained in NIHSS administration will perform an initial assessment 
including history and physical exam, routine labs including glucose level, NIHSS score, 
and inquire about baseline mRS. Baseline demographics will also be collected at this 




Patients will have imaging performed according to standard clinical practice including 
non-contrast head CT with or without CTA based on provider discretion. If consented 
and enrolled in the study, all patients will undergo standardized acute stroke MRI 
including DWI, apparent diffusion coefficient (ADC), FLAIR, SWI. Patients who did not 
have a CTA will also have an MRA done to rule out a large vessel occlusion. The DWI 
sequence will be used to assess potentially salvageable area of ischemia, FLAIR 
sequence will be used to evaluate for tissue infarction, and SWI will be used to evaluate 
for acute or chronic hemorrhage. Non-contrast CT will be repeated at 36 hours to detect 
intracranial hemorrhage.  
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 Symptomatic intracranial hemorrhage will be defined according to the SITS-
MOST trial criteria. These criteria specify presence of parenchymal hemorrhage type II, 
defined by the presence of blood in greater than 30 percent of the infarct area with 
substantial space occupying effect, on imaging 22-36 hours post-treatment combined 
with neurologic decline resulting in a 4-point increase on the NIHSS.22 
 
Data analysis 
Patient demographics and characteristics at baseline will be presented (Table 2). The 
principal outcomes will be evaluated in the intention to treat population (Table 3). The 
primary efficacy outcome of favorable mRS 0 or 1 will be reported as a proportion and 
will be analyzed with a logistic regression model in order to calculate the odds ratio. The 
secondary outcome, the categorical shift on the mRS, will be analyzed with an ordinal 
logistic regression model in order to determine a common odds ratio. This shift analysis 
will demonstrate the probability that treatment with IV alteplase leads to lower mRS 
scores and, thus, less disability than with placebo. Common odds ratios will be adjusted 
for age (18-40 or >40) and time from symptom onset to treatment initiation (4.5-5 hours 
or 5-6 hours).  
 An analysis of the safety outcomes including death and sICH will be performed 
with logical regression modeling. The analyses will also be performed on the per-





Table 2. Patient Characteristics  
Characteristic Alteplase (n=) Placebo (n=) 
Age—yr Mean (SD*) 
Male sex –no. (%) 
Median NIHSS Score (IQR±) 
Medical History— n (%) 
  Hypertension 
  Diabetes mellitus 
  Hypercholesterolemia 
  Atrial fibrillation 
  History of ischemic stroke 
Geographic region—n (%) 
  East Coast 
  West Coast 
  Midwest 
  South 
Time from symptom onset to randomization 
  >4.5 to 5.0 hr 
  >5 to 5.5 hr 
 >5.5 to 6.0 hr 
  
*SD (standard deviation) 
















Timeline and resources 
IRB approval is expected to take three to six months. Recruitment and data collection 
will occur over a period of three years with a further six months dedicated to data 
analysis and manuscript preparation. There will be a primary investigator as well as a co-
investigator at each trial site. A trial coordinator will oversee the project and facilitate 
data and communication between sites. A statistician will perform all of the data analysis 
with patient identity protected with the use of ID codes. Time on an MRI will be required 
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Score or 0-1 on the mRS 
at 90 days 
      
Secondary Outcome 









      
Safety Outcomes 
Death within 90 days  
Symptomatic intracranial 
hemorrhage with 36 hours 
      
*Confidence interval 
Timeline and resources 
IRB approval is expected to take three to six months. Recruitment and data collection 
will occur over a period of three years with a further six months dedicated to data 
analysis and manuscript preparation. There will be a primary investigator as well a co-
investigator at each trial site. A trial coordinator will oversee the project and facilitate 
data and communication between sites. A statistician will perform all of the data analysis 
with patient identity protected with the use of ID codes. Time on an MRI will be required 
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and the time of the radiologists reading the MRI images will also need to be 
compensated. Pharmacists at each site will also be involved and trained on the protocol.  
 
Institutional review board 
Trial protocol will be presented to the Institutional Review Board (IRB) for full board 
review and approval. Special provisions include the use of external investigators given 
that this is a multi-center trial and the inclusion of non-English speaking subjects. The 
trial is not eligible for expedited review because the trial involves more than “minimal 
risk” to subjects. Materials to be submitted to the IRB with the trial application include 





This trial will be the first major clinical trial to assess the efficacy of IV alteplase for the 
treatment of acute ischemic stroke in patients without large vessel occlusions, with DWI-
FLAIR mismatch, between 4.5 and 6 hours of stroke onset. The study is novel in that it 
focuses on patients with lacunar, non-LVO strokes in a delayed time window. Since we 
are including patients over age 80 who have been excluded from previous trials, the 
clinical applicability will be improved. Additionally, the use of clinical sites across the 
country will increase the generalizability of the results. The use of standard MRI 
sequences also allows for easy interpretation of results and generalizability to clinical 
settings compared to CT or MR perfusion studies that are more novel, complicated to 
interpret, and often require expensive interpretation software. However, the limited 
availability of emergent MRI compared to readily accessible CT scanners at many 
hospitals is a weakness of the study. Another weakness is the relative subjectivity of 
DWI-FLAIR mismatch and, without a central image-reading committee, there could be 
selection bias. Lastly, a possibly underpowered sample size is a weakness.  
 An anticipated obstacle to the trial is low enrollment because patients with LVO 
strokes and wake-up stroke will be excluded from the trial. Lacunar strokes only 
comprise approximately 15-25% of all strokes4, so enrollment may be slower than some 
of the preceding stroke treatment trials. Another obstacle may be loss to clinical follow 





In summary, acute ischemic strokes are debilitating events that cause significant long-
term disability and have a high economic burden. Major advancements have been made 
in the field of stroke imaging and treatment, which have helped decrease the morbidity 
and improve functional ability after acute stroke. The use of DWI and FLAIR MRI 
sequences and the advent of perfusion imaging have increased the ability to detect 
salvageable brain tissue and more precisely select patients amenable to treatment with 
mechanical thrombectomy. The treatment window for thrombolytic therapy has also been 
lengthened in response to positive results in clinical trials. When the ECASS-III trial was 
published in 2008, practice changed to allow for treatment with IV alteplase up to 4.5 
hours from last known well and the 2018 WAKE-UP trial changed clinical practice to 
allow IV alteplase treatment for patients with unknown onset time who meet select 
imaging criteria. However, there is still a void in the research and clinical practice 
concerning patients with known stroke onset past 4.5 hours who are not eligible for 
mechanical thrombectomy. This trial will address the needs of this population and 
investigate whether they would benefit from thrombolytic therapy.  
 
Clinical and public health significance 
 It is anticipated that this trial will have a substantial impact on clinical practice. 
The ability to use imaging to risk stratify patients with lacunar strokes who would benefit 
from thrombolytic therapy past 4.5 hours could improve the functional outcomes and 
decrease disability of patients formerly not eligible for treatment. With up to a quarter of 
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stroke patients suffering from lacunar strokes, the benefits could be substantial. 
Additionally, if the trial shows significant and positive results, along with the other trials 
that used DWI-FLAIR and MR-perfusion studies, it could help encourage more hospitals 
















































Level of consciousness (LOC) 0 = Alert 
1 = Not alert, arousable  
2 = Not alert, obtunded  
3 = Unresponsive 
LOC questions (month and age) 0 = Answers both correctly 
1 = Answers one correctly 
2 = Incorrect 
LOC commands  0 = Obeys both correctly 
1 = Obeys one correctly 
2 = Incorrect 
Gaze 0 = Normal 
1 = Partial gaze palsy 
2 = Forces deviation 
Visual Fields 0 = No visual loss 
1 = Partial hemianopsia 
2 = Complete hemianopsia 
3= Bilateral hemianopsia 
Motor arm a) left b) right 0 = No drift 
1 = Drift before 10 seconds 
2 = Falls before 10 seconds 
3 = No effort against gravity 
4 = No movement 
Motor leg a) left b) right  0 = No drift 
1 = Drift before 10 seconds 
2 = Falls before 10 seconds 
3 = No effort against gravity 
4 = No movement 
Ataxia  0 = Absent 
1 = One limb 
2 = Two limbs 
 
Sensory 0 = Normal 
1 = Mild loss 
2 = Severe loss 
Language  0= Normal 
1 = Mild aphasia 
2 = Severe aphasia 
3 = Mute or global aphasia 
Dysarthria 0= Normal 
1 = Mild 
2 = Severe 
Extinction/Inattention 0= Normal 
1 = Mild 
2 = Severe 
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Table 3. Modified Rankin Scale 
 
Score Functional level 
0 No symptoms  
1 No significant disability despite symptoms, can carry out all usual activities 
2 Slight disability, unable to carry out all previous activities, independent with self-care 
3 Moderate disability which requires help, walks without assistance 
4 Moderately severe disability, requires assistance to walk and attend to bodily needs 
5 Severe disability, bedridden, requires constant care 
6 Dead 
(Adapted from Medscape 2019)24 
 
Table 4. Barthel Index 
 
Activity Score 
Feeding 0- Unable 
5- Needs help 
10- Independent 
Bathing 0- Dependent 
5- Independent 
Grooming 0- Needs help with personal care 
5- Independent 
Dressing 0- Dependent 
5- Needs help, can do half unaided 
10- Independent 
Bowels 0- Incontinent 
5- Occasional incontinence 
10- Continent 
Bladder 0- Incontinent 
5- Occasional incontinence 
10- Continent 
Toilet Use 0- Dependent 
5- Needs some help 
10- Independent 
Transfers 0- Unable, no sitting balance 
5- Major help, can sit 
10- Minor help 
15- Independent 
Mobility 0- Immobile or <50 yards 
5- Wheelchair independent 
10- Walks with help of one person  
15- Independent, may use aid 
Stairs 0- Unable 
5- Needs help 
10- Independent 
(Adapted from strokecenter.org 2019)25  
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2 Persistent vegetative state 
3 Severe disability; conscious, but disabled 
4 Moderate disability; disabled but independent 
5 Good recovery despite minor deficits 
(Adapted from Medscape 2019)26  
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